Jean-Mathieu Beauregard
Chercheur universitaire clinicien
Axe Oncologie
Radiologie, médecine nucléaire et imagerie médicale
Oncologie clinique
Publications
View all-
article Zamanian A, Rousseau É and Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Cancer Imaging 25 (1), 2025.
-
article Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, Wang C, Uribe C, Stokke C, Rahmim A, Wong KK, Beauregard JM, Hope TA, Sjögreen Gleisner K, Dewaraja YK
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
J Nucl Med 66 (7), 2025.
-
article Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohor…
Front Oncol 14 2024.
Projects
- Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
- Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2026-03-31
- Tirer profit des données de soins en contexte réel pour une introduction responsable, efficiente et équitable des innovations thérapeutiques en oncologie : la plateforme MEDOnco-VieRéelle, from 2024-09-01 to 2027-08-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, from 2024-09-01 to 2027-08-31
- Les agents theranostiques: anticorps monoclonaux conjugués au médicament et marqués aux radioisotopes 89Zr/225Ac contre le récepteur du facteur de croissance épidermique des cancers colorectal- essai clinique prometteur, from 2024-09-01 to 2027-10-31
- Randomized-controlled, single-blind, pilot study of personalized vs. empiric PSMA-RLT (CAAA617A12102T), from 2025-06-06 to 2030-12-25
- 161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC, from 2025-04-01 to 2030-03-30
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, from 2025-03-11 to 2028-02-29
- Identifying the subgroups of GEP-NET patients that could benefit from temozolomide-induced upregulation of SSTR2 prior to PRRT, from 2025-06-01 to 2027-05-31
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, from 2025-10-01 to 2028-09-30
- Théranostique personnalisée du cancer de la prostate, from 2022-07-01 to 2024-06-30
- Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants, from 2022-04-01 to 2024-12-31
- Screening of gastroenteropancreatic neuroendocrine tumors from patients for temozolomide-induced upregulation of SSTR2: Towards improved PRRT, from 2023-04-01 to 2025-12-31